Teva Pharmaceutical Industries (TEVA) closed at $42.61 on November 6, 2026, up 2.0% from the previous close, on volume of 5,084,874 shares (30-day average 6,621,320).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 26, 2026 | Calendar Call Ladder | 18-Dec-2642 C|15-Jan-2744 : 49 C | 6,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
J.P. Morgan Sticks to Their Buy Rating for Teva (TEVA)
TipRanks (Thu, 5-Nov 4:15 AM ET)
Teva’s Strong Execution and Growth Momentum Drive Buy Rating as Price Target Rises to $54
TipRanks (Wed, 4-Nov 8:15 AM ET)
Teva (TEVA) Gets a Buy from Scotiabank
TipRanks (Wed, 4-Nov 4:26 AM ET)
Teva Earnings Call Signals Stronger Growth Ahead
TipRanks (Tue, 3-Nov 7:19 PM ET)
Teva to buy U.S. rights to two Samsung Bioepis biosimilars
Seeking Alpha News (Tue, 3-Nov 9:16 AM ET)
Teva raises 2026 outlook on strength of innovative brands
Seeking Alpha News (Tue, 3-Nov 7:58 AM ET)
Teva raises 2026 outlook for AUSTEDO, AJOVY and UZEDY after strong Q3 growth
Seeking Alpha News (Tue, 3-Nov 7:24 AM ET)
Globe Newswire (Tue, 3-Nov 7:00 AM ET)
Globe Newswire (Tue, 3-Nov 5:00 AM ET)
Market Chameleon (Mon, 2-Nov 3:19 AM ET)
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Teva Pharmaceutical Industries trades on the NYSE stock market under the symbol TEVA.
As of November 6, 2026, TEVA stock price climbed to $42.61 with 5,084,874 million shares trading.
TEVA has a beta of 0.92, meaning it tends to be less sensitive to market movements. TEVA has a correlation of 0.07 to the broad based SPY ETF.
TEVA has a market cap of $49.70 billion. This is considered a Large Cap stock.
Last quarter Teva Pharmaceutical Industries reported $4 billion in Revenue and $.86 earnings per share. This beat revenue expectation by $146 million and exceeded earnings estimates by $.14.
In the last 3 years, TEVA traded as high as $43.34 and as low as $8.55.
The top ETF exchange traded funds that TEVA belongs to (by Net Assets): IEFA, EFA, EIS, EFG, IXUS.
TEVA has outperformed the market in the last year with a price return of +74.2% while the SPY ETF gained +10.8%. TEVA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +22.4% and +8.1%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
TEVA support price is $40.88 and resistance is $42.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TEVA shares will trade within this expected range on the day.
